Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.51 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 2/20 | 0.49 |
| ▸ | HTR1A | P08908 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | HTR5A | P47898 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9601854 | 0.98 | SIGMAR1 (0.50) | SIGMAR1ADRA2AADRA2BADRA2CTMEM97 | |
| SCHEMBL27645025 | 0.88 | DRD4 (0.56) | SIGMAR1ADRA2AADRA2BTMEM97DRD4 | |
| SCHEMBL30073105 | 0.88 | SIGMAR1 (0.60) | SIGMAR1ADRA2AADRA2BADRA2CTMEM97 | |
| SCHEMBL3692387 | 0.84 | ESR1 (0.58) | SIGMAR1ADRA2AADRA2BADRA2CTMEM97 | |
| SCHEMBL10382855 | 0.81 | SLC6A3 (0.52) | SIGMAR1HTR1ASLC6A3COMTCARM1 | |
| SCHEMBL6672942 | 0.81 | SIGMAR1 (0.62) | SIGMAR1ADRA2AADRA2BADRA2CTMEM97 | |
| Hydrochloric Acid SCHEMBL16713355 | 0.79 | SIGMAR1 (0.60) | SIGMAR1ADRA2AADRA2BADRA2CTMEM97 | |
| SCHEMBL31514906 | 0.79 | SIGMAR1 (0.54) | SIGMAR1ADRA2AADRA2BADRA2CTMEM97 | |
| SCHEMBL10382817 | 0.79 | SIGMAR1 (0.58) | SIGMAR1OPRK1CARM1 | |
| SCHEMBL1206388 | 0.79 | SIGMAR1 (0.54) | SIGMAR1ADRA2AADRA2BADRA2CTMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2528922-B1 | POLYHETEROCYCLIC COMPOUNDS AS HCV INHIBITORS | AB PHARMA LTD (CN) | 2017-08-02 | — | — | EP | disclosed |
| US-8815796-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-08-26 | — | — | US | disclosed |
| US-8815796-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-08-26 | — | — | US | disclosed |
| US-8653025-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-02-18 | — | — | US | disclosed |
| US-8653025-B2 | Polyheterocyclic compounds highly potent as HCV inhibitors | AB Pharma Ltd. (CN) | 2014-02-18 | — | — | US | disclosed |
| WO-2011091757-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-08-04 | — | — | WO | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | AB Pharma Ltd. (CN) | 2011-07-28 | — | — | US | disclosed |
| EP-0227986-B1 | ISOINDOLINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-03-24 | — | — | EP | disclosed |
| US-4987235-A | Isoindoline derivatives and processes for their preparation | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1991-01-22 | — | — | US | disclosed |
| US-4958029-A | Process for the production of isoindoline derivatives, novel intermediates and process for their production | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1990-09-18 | — | — | US | disclosed |
| EP-0275064-A2 | Process for the production of isoindoline derivatives, novel intermediates and process for their production | Banyu Pharmaceutical Co., Ltd. (JP) | 1988-07-20 | — | — | EP | disclosed |
| EP-0227986-A1 | Isoindoline derivatives and processes for their preparation | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110183895-A1 | POLYHETEROCYCLIC COMPOUNDS HIGHLY POTENT AS HCV INHIBITORS | HAVCR2, ZC3HAV1, EIF2AK2 | SIGMAR1 2440/4885ADRA2A 4158/4885ADRA2B 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.